Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Diagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m.
Matured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain.
Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M.
A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Cancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.